The import was conducted in collaboration with
the government of Peru
Magdalena Biosciences is focused on developing
novel, natural prescription medicines derived from plants for
mental health indications
VANCOUVER, BC, Dec. 16,
2024 /CNW/ - Filament Health Corp. (OTCQB:
FLHLF) (Cboe CA: FH) (FSE: 7QS) ("Filament" or "Filament Health"),
a clinical-stage natural psychedelic drug development company,
today announced that Magdalena Biosciences ("Magdalena"), a joint
venture formed by Filament and Jaguar Health, Inc. (Nasdaq: JAGX)
("Jaguar Health"), successfully completed an import of six
kilograms of coca leaf from Peru
to Filament's Metro Vancouver research and development facility.
This is the second import of coca leaf that Magdalena has
completed. It was authorized by the Peruvian Health Authority,
Dirección General de Medicamentos Insumos y Drogas (DIGEMID), and
acquired from the Empresa Nacional de la Coca (ENACO), the only
company in Peru authorized to
distribute coca leaf.
"We are pleased to partner with Filament Health and Magdalena to
facilitate this second import of coca leaf," said Silveria Dongo Gonzales, Technical Director of
ENACO. "We appreciate Filament and Magdalena's diligent efforts in
maintaining a productive relationship with ENACO."
Magdalena was founded on a mission to develop novel, natural
prescription medicines derived from plants for mental health
indications including attention-deficit/hyperactivity disorder
(ADHD) in adults. The coca leaf imported from Peru will be used for the development of a
botanical drug candidate for the treatment of ADHD.
"By importing this significant volume of raw material, we are
able to begin the important work of exploring coca leaf's
therapeutic potential for the treatment of ADHD," said Benjamin Lightburn, Chief Executive Officer of
Filament Health and Magdalena Board Member. "This import was a
significant regulatory achievement by our team and we are grateful
to the Peruvian government for its ongoing partnership."
ABOUT FILAMENT HEALTH (OTCQB:FLHLF) (CBOE:FH)
(FSE:7QS)
Filament Health is a clinical-stage natural
psychedelic drug development company. We believe that safe,
standardized, naturally-derived psychedelic medicines can improve
the lives of many, and our mission is to see them in the hands of
everyone who needs them as soon as possible. Filament's platform of
proprietary intellectual property enables the discovery,
development, and delivery of natural psychedelic medicines. We are
paving the way with what we believe to be the first-ever natural
psychedelic drug candidates.
Learn more at www.filament.health and on Twitter,
Instagram and LinkedIn.
ABOUT MAGDALENA BIOSCIENCES
Jaguar Health, Inc.
and Filament Health Corp. formed Magdalena Biosciences, Inc.
as a joint venture in 2023 to develop novel, natural prescription
medicines derived from plants for mental health indications
including attention-deficit/hyperactivity disorder (ADHD) in
adults. Boulder, Colorado-based
One Small Planet, founded by
Will Peterffy, has committed to
funding of US$1,000,000. The goal of
the collaboration is to extend the botanical drug development
capabilities of Jaguar and Filament in order to develop
pharmaceutical-grade, standardized drug candidates for mental
health disorders.
FORWARD LOOKING INFORMATION
Certain statements and
information contained herein may constitute "forward-looking
statements" and "forward-looking information," respectively, under
Canadian securities legislation. Generally, forward-looking
information can be identified by the use of forward-looking
terminology such as, "expect", "anticipate", "continue",
"estimate", "may", "will", "should", "believe", "intends",
"forecast", "plans", "guidance" and similar expressions are
intended to identify forward-looking statements or information.
Forward-looking statements herein include, but are not limited to,
statements regarding Nagoya Protocol compliance and the outcome of
any coca leaf research. The forward-looking statements are not
historical facts, but reflect the current expectations of
management of Filament regarding future results or events and are
based on information currently available to them. Certain material
factors and assumptions were applied in providing these
forward-looking statements. Forward-looking statements regarding
Filament are based on Filament's estimates and are subject to known
and unknown risks, uncertainties and other factors that may cause
the actual results, levels of activity, performance or achievements
of Filament to be materially different from those expressed or
implied by such forward-looking statements or forward-looking
information, including results of the clinical trial. There can be
no assurance that such statements will prove to be accurate, as
actual results and future events could differ materially from those
anticipated in such statements. Accordingly, readers should not
place undue reliance on forward-looking statements and
forward-looking information. Filament will not update any
forward-looking statements or forward-looking information that are
incorporated by reference herein, except as required by applicable
securities laws.
SOURCE Filament Health Corp.